USPTO Examiner MEYERING SHABANA SHABBEER - Art Unit 1635

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
19216307COMPOSITION FOR REGULATING PRODUCTION OF INTERFERING RIBONUCLEIC ACIDMay 2025January 2026Allow810NoNo
19216250COMPOSITION FOR REGULATING PRODUCTION OF INTERFERING RIBONUCLEIC ACIDMay 2025December 2025Allow710NoNo
19216195COMPOSITION FOR REGULATING PRODUCTION OF INTERFERING RIBONUCLEIC ACIDMay 2025January 2026Allow710NoNo
18971273COMPOSITION FOR REGULATING PRODUCTION OF INTERFERING RIBONUCLEIC ACIDDecember 2024January 2026Allow1310NoNo
18970549COMPOSITION FOR REGULATING PRODUCTION OF INTERFERING RIBONUCLEIC ACIDDecember 2024December 2025Allow1210NoNo
18970618COMPOSITION FOR REGULATING PRODUCTION OF INTERFERING RIBONUCLEIC ACIDDecember 2024January 2026Allow1410NoNo
18970559COMPOSITION FOR REGULATING PRODUCTION OF INTERFERING RIBONUCLEIC ACIDDecember 2024November 2025Allow1210NoNo
18969803COMPOSITION FOR REGULATING PRODUCTION OF INTERFERING RIBONUCLEIC ACIDDecember 2024November 2025Allow1210NoNo
18970411COMPOSITION FOR REGULATING PRODUCTION OF INTERFERING RIBONUCLEIC ACIDDecember 2024December 2025Allow1210NoNo
18969769COMPOSITION FOR REGULATING PRODUCTION OF INTERFERING RIBONUCLEIC ACIDDecember 2024December 2025Allow1210NoNo
18968602COMPOSITION FOR REGULATING PRODUCTION OF INTERFERING RIBONUCLEIC ACIDDecember 2024December 2025Allow1220NoNo
18968659COMPOSITION FOR REGULATING PRODUCTION OF INTERFERING RIBONUCLEIC ACIDDecember 2024December 2025Allow1220NoNo
18968895COMPOSITION FOR REGULATING PRODUCTION OF INTERFERING RIBONUCLEIC ACIDDecember 2024November 2025Allow1110NoNo
18968892COMPOSITION FOR REGULATING PRODUCTION OF INTERFERING RIBONUCLEIC ACIDDecember 2024November 2025Allow1210NoNo
18932316COMPOSITION FOR REGULATING PRODUCTION OF INTERFERING RIBONUCLEIC ACIDOctober 2024October 2025Allow1220NoNo
18932213COMPOSITION FOR REGULATING PRODUCTION OF INTERFERING RIBONUCLEIC ACIDOctober 2024December 2025Allow1320NoNo
18932216COMPOSITION FOR REGULATING PRODUCTION OF INTERFERING RIBONUCLEIC ACIDOctober 2024December 2025Allow1420YesNo
18932368COMPOSITION FOR REGULATING PRODUCTION OF INTERFERING RIBONUCLEIC ACIDOctober 2024December 2025Allow1420YesNo
18931873COMPOSITION FOR REGULATING PRODUCTION OF INTERFERING RIBONUCLEIC ACIDOctober 2024November 2025Allow1220NoNo
18932265COMPOSITION FOR REGULATING PRODUCTION OF INTERFERING RIBONUCLEIC ACIDOctober 2024October 2025Allow1220NoNo
18931989COMPOSITION FOR REGULATING PRODUCTION OF INTERFERING RIBONUCLEIC ACIDOctober 2024April 2025Allow520NoNo
18932105COMPOSITION FOR REGULATING PRODUCTION OF INTERFERING RIBONUCLEIC ACIDOctober 2024January 2026Allow1420YesNo
18777266COMPOSITION FOR REGULATING PRODUCTION OF PROTEINSJuly 2024January 2026Abandon1830NoNo
18768373OLIGONUCLEOTIDES COMPRISING SEGMENTED GAP STRUCTURESJuly 2024January 2026Allow1831YesNo
18643870DIGITAL COUNTING OF INDIVIDUAL MOLECULES BY STOCHASTIC ATTACHMENT OF DIVERSE LABELSApril 2024November 2025Allow1810YesNo
18630828COMPOSITIONS AND METHODS FOR ENHANCING ADOPTIVE T CELL THERAPEUTICSApril 2024January 2025Allow1021YesNo
18610930RNAi Agents for Inhibiting Expression of Complement Factor B (CFB), Pharmaceutical Compositions Thereof, and Methods of UseMarch 2024March 2025Allow1221NoNo
18586486DETECTION ASSAYSFebruary 2024July 2025Allow1720YesNo
18582272COMPOSITION FOR REGULATING PRODUCTION OF INTERFERING RIBONUCLEIC ACIDFebruary 2024November 2025Allow2131NoNo
18518069COMPOSITION FOR REGULATING PRODUCTION OF INTERFERING RIBONUCLEIC ACIDNovember 2023January 2026Allow2641NoNo
18185478COMPOUNDS AND METHODS FOR MODULATING FRATAXIN EXPRESSIONMarch 2023February 2025Abandon2300NoNo
17930672KIT FOR DETECTING FOOT-AND-MOUTH DISEASE VIRUS AND DETECTION METHOD THEREOFSeptember 2022July 2025Abandon3440NoNo
17744634COMPOSITIONS FOR INTRATUMORAL ADMINISTRATION AND RELATED METHODSMay 2022June 2025Abandon3820NoNo
17772763TRANSCRIPTION REGULATORY ELEMENTSApril 2022November 2025Abandon4301NoNo
17620358HYDROXYMETHYL-MODIFIED GAMMA-PNA COMPOSITIONS AND METHODS OF USE THEREOFDecember 2021November 2025Abandon4701NoNo
17441189CHMP2A as a Regulator of Natural Killer Cell-Mediated ActivitySeptember 2021December 2025Abandon5111NoNo
17432794NEUROPROTECTION OF NEURONAL SOMA AND AXON BY MODULATING ER STRESS/UPR MOLECULESAugust 2021September 2025Allow4911YesNo
17431474TARGETING MICRORNAS TO OVERCOME DRUG TOLERANCE AND RESISTANCEAugust 2021July 2025Abandon4701NoNo
17404989ANTISENSE OLIGONUCLEOTIDES FOR MODULATING HTRA1 EXPRESSIONAugust 2021October 2025Abandon5010NoNo
17310354ANTISENSE OLIGONUCLEOIDES OF GLUTATHIONE S-TRANSFERASES FOR CANCER TREATMENTJuly 2021March 2025Abandon4401NoNo
17385277PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER, COMPRISING MIR-324 and TUT4/7 EXPRESSION MODULATORSJuly 2021December 2025Abandon5321NoNo
17425529NRL EXPRESSION REDUCING OLIGONUCLEOTIDES, COMPOSITIONS CONTAINING THE SAME, AND METHODS OF THEIR USEJuly 2021March 2025Abandon4401NoNo
17425494CRISPR-BASED COMPOSITIONS FOR TREATING VASCULAR DISORDERSJuly 2021December 2025Allow5321NoNo
17367201NOVEL METHOD FOR MONITORING ENDOMETRIOSIS AND ASSOCIATED DISORDERSJuly 2021December 2024Abandon4201NoNo
17359775POLYNUCLEOTIDE AGENTS TARGETING COMPLEMENT COMPONENT C5 AND METHODS OF USE THEREOFJune 2021December 2024Abandon4101NoNo
17416286EXPRESSION VECTORS FOR EUKARYOTIC EXPRESSION SYSTEMSJune 2021December 2024Abandon4201NoNo
17415164COMPOSITIONS AND METHODS FOR THE TREATMENT OF KCNT1 RELATED DISORDERSJune 2021December 2024Abandon4201NoNo
17303890CAMK2D ANTISENSE OLIGONUCLEOTIDES AND USES THEREOFJune 2021December 2024Abandon4201NoNo
17057087TREATMENT OF SYNUCLEINOPATHY AND ANIMAL MODELS OF SYNUCLEINOPATHYJune 2021June 2025Abandon5521YesNo
17298114OPTIMIZED mRNA ENCODING CAS9 FOR USE IN LNPsMay 2021November 2024Allow4211YesNo
17309140BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPINGApril 2021February 2025Allow4521YesNo
17234455METHOD FOR PREVENTING OR TREATING CANCER USING SYT11 INHIBITORApril 2021April 2025Allow4820YesNo
17277672QUANTITATIVE REGULATION OF A G PROTEIN SIGNALLING PATHWAYMarch 2021October 2024Abandon4301NoNo
17277474REGULATOR OF TGR5 SIGNALING AS IMMUNOMODULATORY AGENTMarch 2021September 2025Abandon5421YesNo
17277663EXPRESSION VECTORS FOR EUKARYOTIC EXPRESSION SYSTEMSMarch 2021June 2025Allow5121YesNo
17275896PROGRAMMING PROTEIN POLYMERIZATION WITH DNAMarch 2021October 2025Abandon5521NoNo
17273949SCREENING SYSTEM FOR HUMAN-TRANSFORMED CARTILAGE CELL LINE-BASED CARTILAGE DISEASE TREATMENT AGENTSMarch 2021December 2024Abandon4511NoNo
17268592Methods of Managing Nucleic Acid Replication, Expression, and Cleavage Using CRISPR Associated NucleasesFebruary 2021May 2025Abandon5111NoNo
17174961IN SITU SPATIAL BARCODINGFebruary 2021March 2025Allow4941YesNo
17264713METHODS AND COMPOSITIONS FOR TREATING CANCERJanuary 2021February 2026Abandon6021NoNo
17261559GENE THERAPY FOR MACULAR DEGENERATIONJanuary 2021March 2026Allow6040YesNo
17253863Nucleases For Genome EditingDecember 2020September 2024Allow4511YesNo
17103637SCREENING AND APPLICATION OF SGRNA FOR AHI1 GENE EDITINGNovember 2020April 2025Abandon5320NoNo
16970003MODIFIED ADENOVIRUSESAugust 2020January 2025Allow5331YesNo
16963476PHARMACEUTICAL COMPOSITION FOR TREATMENT OF DISEASES ASSOCIATED WITH UPREGULATED PERIOSTIN EXPRESSION OR PERIOSTIN SPLICE VARIANT SWITCHINGJuly 2020December 2024Allow5220YesNo
16909499HELPER PLASMID FOR TRANSFORMATION, METHOD FOR PRODUCING TRANSFORMANT USING THE SAME, AND TRANSFORMATION METHODJune 2020March 2025Allow5741YesNo
16629211INCORPORATION OF UNNATURAL NUCLEOTIDES AND METHODS OF USE IN VIVO THEREOFJanuary 2020April 2025Allow6030YesNo
16711062COMPOUNDS AND METHODS FOR MODULATING FRATAXIN EXPRESSIONDecember 2019November 2024Abandon5920NoNo

Appeals Overview

No appeal data available for this record. This may indicate that no appeals have been filed or decided for applications in this dataset.

Examiner MEYERING, SHABANA SHABBEER - Prosecution Strategy Guide

Executive Summary

Examiner MEYERING, SHABANA SHABBEER works in Art Unit 1635 and has examined 34 patent applications in our dataset. With an allowance rate of 38.2%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 50 months.

Allowance Patterns

Examiner MEYERING, SHABANA SHABBEER's allowance rate of 38.2% places them in the 7% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by MEYERING, SHABANA SHABBEER receive 1.44 office actions before reaching final disposition. This places the examiner in the 23% percentile for office actions issued. This examiner issues significantly fewer office actions than most examiners.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by MEYERING, SHABANA SHABBEER is 50 months. This places the examiner in the 5% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.

Interview Effectiveness

Conducting an examiner interview provides a +80.7% benefit to allowance rate for applications examined by MEYERING, SHABANA SHABBEER. This interview benefit is in the 99% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 30.0% of applications are subsequently allowed. This success rate is in the 58% percentile among all examiners. Strategic Insight: RCEs show above-average effectiveness with this examiner. Consider whether your amendments or new arguments are strong enough to warrant an RCE versus filing a continuation.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 71.4% of cases where such amendments are filed. This entry rate is in the 92% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.

Petition Practice

When applicants file petitions regarding this examiner's actions, 66.7% are granted (fully or in part). This grant rate is in the 71% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 1% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 15.4% of allowed cases (in the 92% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Prioritize examiner interviews: Interviews are highly effective with this examiner. Request an interview after the first office action to clarify issues and potentially expedite allowance.
  • Consider after-final amendments: This examiner frequently enters after-final amendments. If you can clearly overcome rejections with claim amendments, file an after-final amendment before resorting to an RCE.
  • Plan for extended prosecution: Applications take longer than average with this examiner. Factor this into your continuation strategy and client communications.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.